SU011248 Versus Interferon-Alfa As First-Line Systemic Therapy For Patients With Metastatic Renal Cell Carcinoma

NCT00083889

Last updated date
Study Location
Pfizer Investigational Site
Jonesboro, Arkansas, 72401, United States
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Carcinoma, Renal Cell
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Histologically confirmed renal cell carcinoma of clear cell histology with metastases

- Evidence of measurable disease by radiographic technique

- Eastern Cooperative Oncology Group [ECOG] performance status of 0 or 1

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Prior systemic (including adjuvant or neoadjuvant) therapy of any kind for RCC


- History of or known brain metastases


- Serious acute or chronic illness or recent history of significant cardiac abnormality

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Carcinoma, Renal Cell"Retrospective Study to Identify Clinical Factors Related to a High Benefit of Axitinib in mRCC" NCT03538717
  1. Mostoles, Madrid
  2. Orense,
  3. Hospitalet de Llobregat, Barcelona
  4. Sabadell, Barcelona
  5. Tarragona, Barcelona
  6. Terrassa, Barcelona
  7. Alcazar de San Juan, Ciudad REAL
  8. Alcalá de Henares, Madrid
  9. Alcorcón, Madrid
  10. Leganés, Madrid
  11. Parla, Madrid
  12. San Sebatián De Los Reyes, Madrid
  13. Palma de Mallorca, Mallorca
  14. Pamplona, Navarra
  15. La Cuesta, Santa Cruz De Tenerife, Tenerife
  16. Santa Cruz de Tenerife, Tenerife
  17. Talavera de la Reina, Toledo
  18. Barcelona,
  19. Barcelona,
  20. Barcelona,
  21. Barcelona,
  22. Ciudad Real,
  23. Córdoba,
  24. Jaén,
  25. León,
  26. Lugo,
  27. Madrid,
  28. Madrid,
  29. Madrid,
  30. Madrid,
  31. Madrid,
  32. Oviedo,
  33. Santiago de Compostela,
  34. Toledo,
  35. Valencia,
  36. Valencia,
  37. Valencia,
  38. Vigo,
  39. Zaragoza,
  40. Zaragoza,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Carcinoma, Renal CellStudy of Patients With Metastatic and/or Advanced Renal Cell Carcinoma, Treated With Sunitinib/Axitinib. NCT04033991
  1. London,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Carcinoma, Renal CellSU011248 Versus Interferon-Alfa As First-Line Systemic Therapy For Patients With Metastatic Renal Cell Carcinoma NCT00083889
  1. Jonesboro, Arkansas
  2. La Jolla, California
  3. La Jolla, California
  4. Los Angeles, California
  5. San Diego, California
  6. San Francisco, California
  7. Aurora, Colorado
  8. New Haven, Connecticut
  9. New Haven, Connecticut
  10. New Haven, Connecticut
  11. Miami, Florida
  12. Miami, Florida
  13. Tampa, Florida
  14. Chicago, Illinois
  15. Maywood, Illinois
  16. Kansas City, Kansas
  17. Overland Park, Kansas
  18. Louisville, Kentucky
  19. Covington, Louisiana
  20. Metairie, Louisiana
  21. Metairie, Louisiana
  22. Baltimore, Maryland
  23. Boston, Massachusetts
  24. Boston, Massachusetts
  25. Detoit, Michigan
  26. Detroit, Michigan
  27. Farmington Hills, Michigan
  28. Minneapolis, Minnesota
  29. Columbus, Mississippi
  30. Corinth, Mississippi
  31. Jackson, Mississippi
  32. Jackson, Mississippi
  33. Southaven, Mississippi
  34. Tupelo, Mississippi
  35. Kansas City, Missouri
  36. Omaha, Nebraska
  37. Lebanon, New Hampshire
  38. Bronx, New York
  39. New York, New York
  40. New York, New York
  41. Cleveland, Ohio
  42. Cleveland, Ohio
  43. Tulsa, Oklahoma
  44. Tulsa, Oklahoma
  45. Tulsa, Oklahoma
  46. Portland, Oregon
  47. Portland, Oregon
  48. Philadelphia, Pennsylvania
  49. Memphis, Tennessee
  50. Memphis, Tennessee
  51. Nashville, Tennessee
  52. Dallas, Texas
  53. Houston, Texas
  54. Tyler, Texas
  55. Salt Lake City, Utah
  56. Seattle, Washington
  57. Seattle, Washington
  58. Madison, Wisconsin
  59. Lismore, New South Wales
  60. St. Leonards, New South Wales
  61. South Brisbane, Queensland
  62. Woodville South, South Australia
  63. East Melbourne, Victoria
  64. Perth, Western Australia
  65. Victoria,
  66. Rio de Janeiro, RJ
  67. Porto Alegre, RS
  68. Porto Alegre, RS
  69. Calgary, Alberta
  70. Edmonton, Alberta
  71. Kelowna, British Columbia
  72. Vancouver, British Columbia
  73. Victoria, British Columbia
  74. London, Ontario
  75. Toronto, Ontario
  76. Toronto, Ontario
  77. Montreal, Quebec
  78. Quebec,
  79. Quebec,
  80. Paris, Cedex 15
  81. Lyon,
  82. Paris Cedex 13,
  83. Rennes,
  84. Saint Herblain,
  85. Vandoeuvre Les Nancy,
  86. Aachen,
  87. Essen,
  88. Hannover,
  89. Ulm,
  90. Ulm,
  91. Modena,
  92. Napoli,
  93. Pavia,
  94. Roma,
  95. Roma,
  96. Roma,
  97. Moczowego, Warszawa
  98. Gdansk,
  99. Krakow,
  100. Lodz,
  101. Lublin,
  102. Poznan,
  103. Warszawa,
  104. Wroclaw,
  105. Wroclaw,
  106. Obninsk, Kaluga Region
  107. Chelyabinsk,
  108. Moscow,
  109. Moscow,
  110. Moscow,
  111. Saint-Petersburg,
  112. St. Petersburg,
  113. Tomsk,
  114. Hospitalet de Llobregat, Barcelona
  115. Pamplona, Navarra
  116. Madrid,
  117. Madrid,
  118. Sevilla,
  119. Whitchurch, Cardiff
  120. Manchester, Lancashire
  121. Northwood, Middlesex
  122. London,
  123. London,
  124. Sutton Surrey,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE SU011248 Versus Interferon-Alfa As First-Line Systemic Therapy For Patients With Metastatic Renal Cell Carcinoma
Official Title  ICMJE A Phase 3, Randomized Study Of SU011248 Versus Interferon-Alfa As First-Line Systemic Therapy For Patients With Metastatic Renal Cell Carcinoma
Brief Summary The purpose of this study is to test whether SU011248 has activity and is safe compared to interferon-alfa as first-line therapy in patients with metastatic renal cell carcinoma (RCC).
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Carcinoma, Renal Cell
Intervention  ICMJE
  • Drug: Interferon-alfa
    3 MIU first week, 6 MIU second week, and 9 MIU thereafter three times a week (non-consecutive days) until progression or unacceptable toxicity
    Other Name: Roferon
  • Drug: SU011248
    50 mg orally daily for 4 weeks and 2 weeks off treatment until progression or unacceptable toxicity
    Other Name: Sunitinib, SUTENT
Study Arms  ICMJE
  • Active Comparator: 2
    Intervention: Drug: Interferon-alfa
  • Experimental: 1
    Intervention: Drug: SU011248
Publications *

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: November 6, 2009)
750
Original Enrollment  ICMJE Not Provided
Actual Study Completion Date  ICMJE September 2008
Actual Primary Completion Date September 2008   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Histologically confirmed renal cell carcinoma of clear cell histology with metastases
  • Evidence of measurable disease by radiographic technique
  • Eastern Cooperative Oncology Group [ECOG] performance status of 0 or 1

Exclusion Criteria:

  • Prior systemic (including adjuvant or neoadjuvant) therapy of any kind for RCC
  • History of or known brain metastases
  • Serious acute or chronic illness or recent history of significant cardiac abnormality
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Australia,   Brazil,   Canada,   France,   Germany,   Italy,   Poland,   Russian Federation,   Spain,   United Kingdom,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00083889
Other Study ID Numbers  ICMJE A6181034
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Director, Clinical Trial Disclosure Group, Pfizer Inc
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date January 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP